Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
Iambic Therapeutics
Accelerates drug discovery through generative AI and high-throughput physics models.
What they do
Iambic Therapeutics operates an AI-driven drug discovery platform that integrates physics-based machine learning with automated chemistry. Pharmaceutical partners use their technology to rapidly design molecules with optimized drug-like properties, therapeutic efficacy, and favorable toxicology profiles.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- San Diego, USA
- Region
- North America
- Founded
- 2019
- Total funding
- $152M raised
Notable investors: Nvidia, Coatue, OrbiMed, Illumina Ventures.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
The Digital Therapeutics Evidence Gap: What FDA Authorization Actually Required
Dr. Dereck Mush, MD, MBA